Daily non-political popular news in brief.
SCAI president testifies before FDA on safety of drug-eluting stents
12-07-2006 · EurekAlert!In testimony before the Food and Drug Administration (FDA), Gregory J. Dehmer, MD, president of the Society for Cardiovascular Angiography and Interventions (SCAI), today urged a review panel to evaluate new data on the safety of drug-eluting stents (DES) from the perspective of prior developments in the history of coronary intervention, and with an appreciation for the balance of benefits and risks that guides all clinical decision-making.
Read more »
Keywords: scai, president, testifies, fda, safety, drug-eluting, stents, testify, drug, eluting, stent
« Previous | Next »
Similar news on "SCAI president testifies before FDA on safety of drug-eluting stents":
- SCAI issues clinical alert on drug-eluting stents and late thrombosis
01-11-2007 · EurekAlert!
The Society for Cardiovascular Angiography and Interventions (SCAI) today released a clinical alert advising physicians on practical steps for reducing the risk of a rare but serious complication associated with drug-eluting stents. The document follows hearings held by the FDA's Circulatory Systems Device Panel. SCAI's clinical alert focuses on careful patient selection, meticulous stent implantation, and consistent use of medications to prevent the delayed formation of blood clots that can block blood flow to the heart.
Similar news · Read more »
- Bioabsorbable stent shows excellent performance
03-24-2007 · EurekAlert!
The use of slow-release drugs in stents (drug-eluting stents) has dramatically reduced restenosis rates after percutaneous coronary intervention. However, these permanent metal devices may impair coronary imaging, predispose patients to late stent thrombosis, prevent positive remodeling and hinder revascularization. A study presented today at the American College of Cardiology's Innovation in Intervention: i2Summit assesses the safety and performance of a bioabsorbable stent that, if effective, could eliminate several of the problems associated with metallic stents.
Similar news · Read more »
- Second-generation drug-eluting stent system challenges current gold standard
03-24-2007 · EurekAlert!
While research shows that drug-eluting stents effectively reduce restenosis and revascularization compared to bare-metal stents, questions surrounding the safety of drug-eluting stents continue to dominate headlines. A study presented today at the American College of Cardiology’s Innovation in Intervention: i2 Summit surveys the safety and efficacy of the second generation Xience Everolimus Eluting Coronary Stent System (EES), compared to the current gold standard paclitaxel-eluting stent (PES), to determine if it offers similar or enhanced outcomes.
Similar news · Read more »
- Studies highlight 'real world' use, safety of drug-eluting stents
03-26-2007 · EurekAlert!
Research presented today at the American College of Cardiology’s Innovation in Intervention: i2 Summit 2007 in New Orleans, La, paints a picture of the "real world" use of drug-eluting stents and offers new insight into the connection between blood clotting, or thrombosis, in the stent -- a dangerous complication -- and adherence and responsiveness to anti-clotting medication.
Similar news · Read more »
- Second generation drug-eluting stent system challenges current gold standard
03-24-2007 · EurekAlert!
While research shows that drug-eluting stents effectively reduce restenosis and revascularization compared to bare-metal stents, questions surrounding the safety of drug-eluting stents continue to dominate headlines. A study presented today at the American College of Cardiology’s Innovation in Intervention: i2 Summit surveys the safety and efficacy of the second generation Xience Everolimus Eluting Coronary Stent System (EES), compared to the current gold standard paclitaxel-eluting stent (PES), to determine if it offers similar or enhanced outcomes.
Similar news · Read more »
- Risk and outcome similar for bypass surgery, drug-eluting stents
04-19-2007 · EurekAlert!
Drug-eluting stent therapy and bypass surgery for coronary artery disease have about the same risk for a major cardiac event within 30 days after the procedures, researchers reported at the American Heart Association's 8th annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology.
Similar news · Read more »
- Studies led by Rhode Island Hospital confirm safety and efficacy
11-17-2006 · EurekAlert!
Following two studies of patients who were treated with cardiac stents, physicians at Rhode Island Hospital continue to recommend drug-eluting stents as a safe and effective treatment.
Similar news · Read more »
- Tip sheet, Annals of Internal Medicine, Dec. 18, 2007, issue
12-17-2007 · EurekAlert!
The following articles are in the upcoming issue of Annals of Internal Medicine: "Task Force Does Not Recommend Screening for Carotid Artery Stenosis"; "Vitamin D is Standard Treatment for CKD Despite Evidence"; "Organ Donation Laws Need Revising so that Doctors Give Priority to Care for the Donor Rather than The Organ"; "Study Finds Insufficient Evidence to Decide the Most Effective Treatment to Prevent Osteoporotic Fractures"; and "Balancing Efficacy and Safety of Drug-Eluting Stents."
Similar news · Read more »
- Patients who receive drug-eluting stents should continue antiplatelet medications
01-16-2007 · EurekAlert!
Patients who have had drug-eluting stents inserted to prop open blocked coronary arteries should continue to take medications to reduce the risk of blood clots for at least one year after the stent is inserted, a new scientific advisory recommends.
Similar news · Read more »
- SCAI leaders available for comment on studies released at European Society for Cardiology Congress
09-02-2007 · EurekAlert!
New studies and clinical trials and data to be released on interventional cardiology, percutaneous intervention (PCI), including use of angioplasty, renal artery stenting, bare metal stents and drug eluting stents.
Similar news · Read more »
